Regeneron (REGN) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseZacks Investment Research · 1 day ago
Regeneron: Is The Market Undervaluing Its Growth PotentialSeeking Alpha · 2 days ago
Forget Eli Lilly and Novo: This Biotech Could Be a Surprising Winner in the Weight Loss MarketThe Motley Fool · 5 days ago
Frank Rimerman Advisors LLC Acquires 876 Shares of Regeneron Pharmaceuticals, Inc. $REGNDefense World · 5 days ago
Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Insider Sells $3,204,386.90 in StockDefense World · 6 days ago
Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)Defense World · 6 days agoRegeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients.
| Date | Est. | Actual | |
|---|---|---|---|
| Jul 30, 2026 | $10.16 | $14.29 | Beat |
| Apr 29, 2026 | $8.91 | $9.47 | Beat |
| Jan 30, 2026 | $10.74 | $11.44 | Beat |
| Oct 28, 2025 | $9.65 | $11.83 | Beat |
| Aug 1, 2025 | $8.43 | $12.89 | Beat |
| Apr 29, 2025 | $8.62 | $8.22 | Miss |